Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe version history now shows an addition of Revision: v3.4.3 and removal of Revision: v3.4.2.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedStudy Status updated to Completed on 2026-02-25 and Recruitment Status updated accordingly, replacing the previous Active, not recruiting status.SummaryDifference0.2%

- Check29 days agoChange DetectedAn administrative update adds Revision: v3.4.2 to the history and removes the earlier funding/operating-status notice, reflecting system maintenance rather than study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check36 days agoChange DetectedSite-wide notice about government funding lapse was added, and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check43 days agoChange DetectedUI tweaks include showing the glossary, explaining color-coded highlights, and updating the revision label to v3.4.0; a capitalization change from 'No FEAR Act data' to 'No FEAR Act Data' was made.SummaryDifference0.3%

- Check57 days agoChange DetectedThe page history now includes an entry for Revision: v3.3.4 and the entry for Revision: v3.3.3 was removed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.